mesalamine · Abbvie · NDA 021252
Canasa
Earliest generic entry, as listed
6 Jun 2028
Blocked by patent: US 8217083, US 8436051.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8217083 | product | 6 Jun 2028 |
| US 8436051 | product | 6 Jun 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021252 · 001 · discontinued | suppository, rectal | 500MG | open |
| 021252 · 002 · RLD | suppository, rectal | 1GM | 6 Jun 2028 |